Incyte (Nasdaq:INCY) today announced that multiple abstracts
featuring new data from the company’s clinical program on
povorcitinib, an investigational oral JAK-1 inhibitor, have been
accepted for oral presentation at the 8th Annual Symposium on
Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in
Phoenix.
“We look forward to sharing data from three oral presentations
which add to our body of evidence on povorcitinib as a potential
effective oral treatment option for patients living with
hidradenitis suppurativa (HS),” said Kurt Brown, M.D., Global
Program Head, Povorcitinib, and Associate Vice President, Drug
Development, Inflammation & AutoImmunity, Incyte. “At Incyte,
we are committed to relentlessly following the science to explore
potential treatment options for immune-mediated dermatologic
conditions such as HS, and are excited to share these data with the
scientific community at this year’s SHSA.”
Key abstracts from Incyte-sponsored programs include:
Oral & Poster
Presentations
Povorcitinib Impact on DLQI in Patients with Hidradenitis
Suppurativa: Placebo-Controlled Phase 2 Study Results (Session:
Clinical Research - Observational, Trials, and Treatment. Friday
October 13, 4:00 p.m. – 4:10 p.m. ET)
HiSQoL Changes Among HiSCR Responders and Nonresponders in a
Phase 2 Study of Povorcitinib (Session: Clinical Research -
Observational, Trials, and Treatment. Friday October 13, 4:20 p.m.
– 4:30 p.m. ET)
Baseline Patient Characteristics Associated with Achieving
HiSCR with Povorcitinib: Phase 2 Secondary Analysis (Session:
Clinical Research - Observational, Trials, and Treatment. Saturday
October 14, 2:55 p.m. – 3:05 p.m. ET)
For full session details and data presentation listings, please
see the SHSA 2023 (https://shsa.joynsymposium.com/conference_hall)
online program.
About Hidradenitis Suppurativa Hidradenitis suppurativa
(HS) is a chronic inflammatory skin condition characterized by
painful nodules and abscesses that can lead to irreversible tissue
destruction and scarring1,2. Over-activity of the JAK/STAT
signaling pathway is believed to drive inflammation involved in the
pathogenesis and progression of HS3. More than 150,000 patients in
the U.S. are estimated to have moderate to severe HS4. Given the
debilitating nature of condition, it can have a profoundly negative
effect on patients’ quality of life5.
About Povorcitinib (INCB54707) Povorcitinib (INCB54707)
is an oral small-molecule JAK1 inhibitor currently in Phase 2
clinical trials for vitiligo, hidradenitis suppurativa (HS),
prurigo nodularis, chronic spontaneous urticaria and asthma. Phase
3 studies in HS are also ongoing.
About Incyte Dermatology Incyte’s science-first approach
and expertise in immunology has formed the foundation of the
company. Today, we are building on this legacy as we discover and
develop innovative dermatology treatments to bring solutions to
patients in need.
Our research and development efforts in dermatology are
initially focused on leveraging our knowledge of the JAK-STAT
pathway. We are exploring the potential of JAK inhibition for a
number of immune-mediated dermatologic conditions with a high unmet
medical need, including atopic dermatitis, vitiligo, hidradenitis
suppurativa, lichen planus, lichen sclerosus and prurigo
nodularis.
To learn more, visit the Dermatology section of Incyte.com.
About Incyte Incyte is a Wilmington, Delaware-based,
global biopharmaceutical company focused on finding solutions for
serious unmet medical needs through the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit Incyte.com and follow
@Incyte.
Forward-Looking Statements Except for the historical
information set forth herein, the matters set forth in this press
release, including statements regarding the presentation of data
from Incyte’s clinical development pipeline, whether or when any
development compounds or combinations will be approved or
commercially available for use in humans anywhere in the world,
Incyte’s dermatology program generally, and Incyte’s goal of
improving the lives of patients, contain predictions, estimates and
other forward-looking statements.
These forward-looking statements are based on Incyte’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments in and risks related to: unanticipated delays; further
research and development and the results of clinical trials
possibly being unsuccessful or insufficient to meet applicable
regulatory standards or warrant continued development; the ability
to enroll sufficient numbers of subjects in clinical trials;
determinations made by the FDA, EMA and other regulatory
authorities; the efficacy or safety of Incyte’s products; the
acceptance of Incyte’s products in the marketplace; market
competition; sales, marketing, manufacturing and distribution
requirements; and other risks detailed from time to time in
Incyte’s reports filed with the Securities and Exchange Commission,
including its annual report and its quarterly report on Form 10-Q
for the quarter ended June 30, 2023. Incyte disclaims any intent or
obligation to update these forward-looking statements.
________________________________ 1 National Center for Advancing
Translational Science Genetic and Rare Diseases Information Center.
“Hidradenitis suppurativa.” Available at:
https://rarediseases.info.nih.gov/diseases/6658/hidradenitis-suppurativa
2 Kirby J, et al. Efficacy and Safety of the Janus Kinase 1
Inhibitor Povorcitinib (INCB054707) in Patients with Hidradenitis
Suppurativa: Results from a Randomized, Placebo-Controlled, Phase 2
Dose-Ranging Study. Presented at the 31st European Academy of
Dermatology and Venereology (EADV) Congress, September 7-10, 2022.
3 Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging
topical and systemic JAK inhibitors in dermatology. Frontiers in
immunology, 10, 2847. 4 McMillan, K. Hidradenitis suppurativa:
number of diagnosed patients, demographic characteristics, and
treatment patterns in the United States. Am J Epidemiol. 2014 Jun
15;179(12):1477-83. doi: 10.1093/aje/kwu078. Epub 2014 May 8. 5
Sabat, R., Jemec, G. B., Matusiak, Ł., Kimball, A. B., Prens, E.,
& Wolk, K. (2020). Hidradenitis suppurativa. Nature reviews
Disease primers, 6(1), 18.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231013811765/en/
Media media@incyte.com
Investors ir@incyte.com
Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024